Below are the most recent publications written about "Nuclear Receptor Coactivator 3" by people in Profiles.
-
Qin L, Chen J, Lu D, Jain P, Yu Y, Cardenas D, Peng X, Yu X, Xu J, Wang J, O'Malley BW, Lonard DM. Development of improved SRC-3 inhibitors as breast cancer therapeutic agents. Endocr Relat Cancer. 2021 08 13; 28(10):657-670.
-
Gilad Y, Eliaz Y, Yu Y, Dean AM, Han SJ, Qin L, O'Malley BW, Lonard DM. A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells. Commun Biol. 2021 03 25; 4(1):399.
-
Mullany LK, Lonard DM, O'Malley BW. Wound Healing-related Functions of the p160 Steroid Receptor Coactivator Family. Endocrinology. 2021 03 01; 162(3).
-
Liu J, Xie Y, Guo J, Li X, Wang J, Jiang H, Peng Z, Wang J, Wang S, Li Q, Ye L, Zhong Y, Zhang Q, Liu X, Lonard DM, Wang J, O'Malley BW, Liu Z. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.
-
Nikolai BC, Jain P, Cardenas DL, York B, Feng Q, McKenna NJ, Dasgupta S, Lonard DM, O'Malley BW. Steroid receptor coactivator 3 (SRC-3/AIB1) is enriched and functional in mouse and human Tregs. Sci Rep. 2021 02 09; 11(1):3441.
-
Sawant Dessai A, Dominguez MP, Chen UI, Hasper J, Prechtl C, Yu C, Katsuta E, Dai T, Zhu B, Jung SY, Putluri N, Takabe K, Zhang XH, O'Malley BW, Dasgupta S. Transcriptional Repression of SIRT3 Potentiates Mitochondrial Aconitase Activation to Drive Aggressive Prostate Cancer to the Bone. Cancer Res. 2021 01 01; 81(1):50-63.
-
Yu X, Yi P, Hamilton RA, Shen H, Chen M, Foulds CE, Mancini MA, Ludtke SJ, Wang Z, O'Malley BW. Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes. Mol Cell. 2020 09 03; 79(5):812-823.e4.
-
Lee WK, Kim WG, Fozzatti L, Park S, Zhao L, Willingham MC, Lonard D, O'Malley BW, Cheng SY. Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer. Endocr Relat Cancer. 2020 04; 27(4):209-220.
-
Blundon MA, Dasgupta S. Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis. Endocrinology. 2019 08 01; 160(8):1811-1820.
-
Song X, Chen H, Zhang C, Yu Y, Chen Z, Liang H, Van Buren G, McElhany AL, Fisher WE, Lonard DM, O'Malley BW, Wang J. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Cancer Lett. 2019 02 01; 442:310-319.